Esmolol

اسمولول

⚠ Unverified

❤️ Cardiovascular SystemShort-acting IV beta-blocker

Market / country: 🇺🇸 USA

Brevibloc (US)

🧮 Dose calculator

Paroxysmal supraventricular tachycardia · Regimen source: FDA Brevibloc · 2.1

  • • Optional load 500 mcg/kg over 1 min, then 50 mcg/kg/min for 4 min; titrate at ≥4-min intervals by rate or BP. FDA Brevibloc · 2.1

Enter age and weight.

🛡️ Safety & information

Contraindications

  • ⛔ Severe sinus bradycardia; heart block above first degree; sick sinus syndrome; decompensated heart failure; cardiogenic shock; pulmonary hypertension; recent IV verapamil. FDA Brevibloc · 4

Formulations

  • 10 mg/mL premixed bag or vial (10,000 mcg/mL) — injection 🇺🇸 USA FDA Brevibloc · 3
  • 20 mg/mL double-strength bag (20,000 mcg/mL) — injection 🇺🇸 USA FDA Brevibloc · 3

👥 Special populations

  • 🤰 PregnancyUse with caution

    Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Brevibloc · 8.1

    “BREVIBLOC injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”
  • 🤱 BreastfeedingDangerous / avoid

    Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Brevibloc · 8.3

    “Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from BREVIBLOC injection, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.”
  • 👶 ChildrenSafety not established

    Label: safety and effectiveness in children have not been established. FDA Brevibloc · 8.4

    “The safety and effectiveness of BREVIBLOC injection in pediatric patients have not been established.”
  • 👴 Older adultsUse with caution

    Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Brevibloc · 8.5

    “In general, dose selection for an elderly patient should usually start at the low end of the dosing range, reflecting greater frequency of decreased renal or cardiac function and of concomitant disease or other drug therapy.”
  • ⚥ Females & males of reproductive potentialNo data

    The source for this drug has no section for this group.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

🔗 Similar drugs

Doz is only a support tool and does not replace clinical judgment or official sources. Check every dose against the original source before prescribing. About & disclaimer · Sources

Information on this site is compiled from online websites and references. Doz accepts no responsibility for self-medication without approval from a physician and a reliable reference, or for any consequences of using this information.

Inspired by the Saphira project; part of the content is taken from it.

For suggestions, corrections, adding drugs or anything else, you can contact me on Telegram: @cenaav